SLC5A2 and hydrops fetalis: Research in recent years has found that SGLT-2 inhibitors have the power to reduce the risk of cardiovascular outcomes and mortality (Mascolo et al., 2021), especially on HF patients who could gain benefits from therapy treatment with dapagliflozin and empagliflozin (Packer et al., 2020; Butt et al., 2021).